BIOGEN INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
BIOGEN INC. (BIIB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $10.90 million for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-05.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2013-02-05
- BIOGEN INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2012 was $10.90M, a 0.93% increase from fiscal 2011.
- BIOGEN INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2011 was $10.80M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2012-12-31 | $10.90M 10-K · filed 2013-02-05 |
| 2011-12-31 | $10.80M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |